Paul M Beringer (P M Beringer, Paul Beringer)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Venues

CPT: pharmacometrics & systems pharmacology

Antimicrobial agents and chemotherapy

Clinical pharmacology and therapeutics

American journal of respiratory cell and molecular biology

University of Southern California

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Southern California Sep 01 1992

United States

Professor and Chair :: Department of Clinical Pharmacy

Publications

Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Marco Zampoli, Paul M Beringer
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clinical pharmacology and therapeutics (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Marco Zampoli, Paul M Beringer
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Clinical pharmacology and therapeutics 115 (6) (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Paul M Beringer
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Eunjin Hong, Regina Li, Alan Shi, Lisa M Almond, Joshua Wang, Amin Z Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S Chung, Adupa P Rao, Paul M Beringer
Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Pharmacotherapy (2023)
Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S Chung, Adupa P Rao, Kevin Forrester, Paul M Beringer
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients. Pharmaceutics 15 (5) (2023)
Eunjin Hong, Alan Shi, Paul M Beringer
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications. Expert opinion on drug metabolism & toxicology (2023)
A Young J Park, Dat Q Tran, Justin B Schaal, Mengxi Wang, Michael E Selsted, Paul M Beringer
Preclinical Pharmacokinetics and Safety of Intravenous RTD-1. Antimicrobial agents and chemotherapy 66 (3) (2022)
E Hong, L M Almond, P S Chung, A P Rao, Paul M Beringer
Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria. Antimicrobial agents and chemotherapy 66 (11) (2022)
Mansour A Dughbaj, Jordanna G Jayne, A Young J Park, Timothy J Bensman, Marquerita Algorri, Andre J Ouellette, Michael E Selsted, Paul M Beringer
Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis. Antibiotics (Basel, Switzerland) 10 (9) (2021)
Jordanna G Jayne, Timothy J Bensman, Justin B Schaal, A Young J Park, Elza Kimura, Dat Tran, Michael E Selsted, Paul M Beringer
Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. American journal of respiratory cell and molecular biology 58 (3) (2018)

Paul M Beringer.css-eqlu8i{font-size:small;padding-left:4px;} (P M Beringer, Paul Beringer)

Publication Activity (10 Years)

Top Topics

Top Venues

Paul M Beringer (P M Beringer, Paul Beringer)